Alternatives to Ozempic, Wegovy, Mounjaro and Zepbound

First, work out which question you are asking

Same molecule, lower price. You want Wegovy but not at retail. This is by far the most common case and it has good answers.

Different molecule, similar class. You did not tolerate one agent, or it did not work. A different incretin agent is a reasonable clinical conversation.

Different approach entirely. You cannot take these drugs, cannot afford them, or do not want to. Real options exist but expect meaningfully smaller effects.

Same molecule, lower price

Manufacturer self-pay pharmacies. NovoCare Pharmacy publishes Wegovy from $149/month for 1.5 mg and 4 mg tablets, $199/month for new patients' first two injection fills, then $349/month, with free shipping and no prior authorisation. LillyDirect operates a comparable route for Zepbound. Check these before anything else.

Manufacturer savings programmes. Novo publishes a commercial savings offer of as little as $25/month with a $100 maximum monthly saving. Government beneficiaries are excluded.

Telehealth providers passing through manufacturer pricing. Sesame publishes the same $199-then-$349 structure and references NovoCare directly. Mochi publishes Ozempic at $199 and Wegovy at $299.

Compounded preparations. The cheapest route — $60 to $299/month across providers we verified — but these are not FDA-approved products and are not evaluated by FDA for safety, efficacy or quality. Read our compounded vs branded guide before choosing this.

Different molecule, similar class

Liraglutide (Saxenda, Victoza). A first-generation daily GLP-1 with roughly half the weight effect of the weekly agents, but generic availability has made it the cheapest genuine GLP-1. Daily injection is the adherence trade-off. Ivím lists compounded liraglutide; WeightWatchers and PlushCare carry branded Saxenda.

Switching between semaglutide and tirzepatide. If one did not work or was not tolerated, the other is a legitimate clinical option. See our semaglutide vs tirzepatide guide.

Oral GLP-1s. Wegovy pill and Rybelsus are oral semaglutide formulations; Foundayo (orforglipron) is an oral agent several providers now list. Mochi publishes compounded orforglipron at $52 and Wegovy Pill at $149; NovoCare publishes Wegovy tablets at $149/month. Worth considering if injection is the barrier.

Genuinely different approaches

Metformin. Not a weight-loss drug and not equivalent to an incretin, but inexpensive, long-established, and a reasonable first step for people with glycemic indications. Mochi publishes it at $13/month; Lemonaid at $90 per three months.

Naltrexone/bupropion combinations. WeightWatchers lists these among its non-GLP-1 options. Smaller average effect than incretin therapy, different side-effect profile.

Structured behavioural programmes. WeightWatchers bundles nutrition counselling, fitness planning and workshops into its membership. The effect sizes are smaller than pharmacotherapy but the cost is far lower and there is no drug to discontinue.

Doing nothing yet. If you do not meet clinical criteria, the honest answer may be that these drugs are not indicated for you. A BMI threshold exists for a reason.

What to be careful of

Be sceptical of anything marketed as a natural or over-the-counter GLP-1. These are prescription peptide medications; supplements claiming equivalent effects are not equivalent.

Be equally careful with sellers offering research-grade peptides. Material sold as not-for-human-use has no quality assurance for human administration.

If price is the driver, work down the legitimate ladder first: manufacturer self-pay, savings programmes, generic liraglutide, then compounded from a provider that will tell you which pharmacy prepares it.